Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Halozyme Therapeutics, Inc. (HALO)

40.42   1.38 (3.53%) 05-16 07:16
Open: 39.73 Pre. Close: 39.04
High: 40.58 Low: 39.415
Volume: 1,101,626 Market Cap: 5,576(M)
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 40.58 - 40.73 40.73 - 40.85
Low: 39.01 - 39.19 39.19 - 39.36
Close: 40.13 - 40.38 40.38 - 40.62

Technical analysis

as of: 2022-05-13 4:38:41 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 48.78     One year: 52.25
Support: Support1: 36.95    Support2: 30.74
Resistance: Resistance1: 41.76    Resistance2: 44.74
Pivot: 40.48
Moving Average: MA(5): 38.71     MA(20): 41.09
MA(100): 37.68     MA(250): 39.09
MACD: MACD(12,26): -0.4     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 30.7     %D(3): 21.2
RSI: RSI(14): 50.8
52-week: High: 46.61  Low: 31.36
Average Vol(K): 3-Month: 929 (K)  10-Days: 1,128 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ HALO ] has closed above bottom band by 49.1%. Bollinger Bands are 28.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 16 May 2022
How to Unlock Clippy Items in Halo Infinite | Screen Rant - Screen Rant

Mon, 16 May 2022
Lack of trust, dysfunction and naïveté broke eUnited's Halo roster - Gaming Trend

Sun, 15 May 2022
10 Worst Items In The Halo Infinite Lone Wolves Battle Pass - CBR - Comic Book Resources

Sun, 15 May 2022
'Halo: Infinite' Creative Lead Hints At The Return Of Classic Maps - Boss Hunting

Sun, 15 May 2022
'Halo' Episode 9 Release Date and Time: Finale Teases Epic Covenant Battle - Showbiz Cheat Sheet

Sun, 15 May 2022
Halo: 10 Cortana And Chief Quotes That Prove They Have The Best Relationship - Screen Rant

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 141 (M)
Shares Float 139 (M)
% Held by Insiders 0.9 (%)
% Held by Institutions 95.5 (%)
Shares Short 6,510 (K)
Shares Short P.Month 5,990 (K)

Stock Financials

EPS 2.77
EPS Est Next Qtl 0.27
EPS Est This Year -0.13
EPS Est Next Year -0.8
Book Value (p.s.) 2
Profit Margin (%) 88.3
Operating Margin (%) 64.1
Return on Assets (ttm) 21.7
Return on Equity (ttm) 214.9
Qtrly Rev. Growth 77.3
Gross Profit (p.s.) 1.34
Sales Per Share 3.28
EBITDA (p.s.) 2.11
Qtrly Earnings Growth 492
Operating Cash Flow 268 (M)
Levered Free Cash Flow 153 (M)

Stock Valuations

PE Ratio 14.53
PEG Ratio 1
Price to Book value 20.2
Price to Sales 12.29
Price to Cash Flow 21.24

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.